Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing ...

BeiGene enters global licensing agreement CSPC Zhongqi Pharmaceutical for MAT2A inhibitor for solid tumours: San Mateo, California Saturday, December 14, 2024, 12:00 Hrs [IST] Bei ...

Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264 ...

Evariste, a TechBio using mathematics and AI to design small molecule therapeutics, has entered into a preclinical research ...

Bayer initiates phase I study with SOS1 inhibitor, BAY3498264 in patients with advanced KRAS-mutated tumours: Berlin Saturday, December 14, 2024, 13:00 Hrs [IST] Bayer announced i ...

Tasca Therapeutics Corp. (“Tasca”), a biotechnology company leveraging a unique drug discovery platform that identifies and ...

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven ...

Insilico Medicine (‘Insilico’), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and ...

Orion Corporation has teamed up with Evariste. Takeaway Points  Orion Corporation teams up with Evariste. Evariste will use ...